Medicine & Life Sciences

1. Sarcoma 100%
2. Neoplasms 36%
3. Drug Therapy 33%
4. Osteosarcoma 33%
5. Survival 32%
6. Gastrointestinal Stromal Tumors 32%
7. pazopanib 26%
8. Ewing's Sarcoma 25%
9. Progression-Free Survival 25%
10. Radiotherapy 23%
11. gemcitabine 23%
12. Therapeutics 22%
13. regorafenib 20%
14. Leiomyosarcoma 18%
15. TH 302 17%
16. Doxorubicin 16%
17. Imatinib Mesylate 15%
18. Aggressive Fibromatosis 15%
19. Liposarcoma 12%
20. Hemangiosarcoma 11%
21. Placebos 11%
22. mocetinostat 11%
23. Confidence Intervals 10%
24. Stomatitis 10%
25. Myxoid Liposarcoma 10%
26. Recurrence 10%
27. Safety 10%
28. Squamous Cell Carcinoma of Head and Neck 9%
29. Bevacizumab 9%
30. Squamous Cell Carcinoma 9%
31. Small Cell Lung Carcinoma 9%
32. Synovial Sarcoma 9%
33. Cisplatin 9%
34. Neurofibrosarcoma 8%
35. Survival Rate 8%
36. pembrolizumab 8%
37. temsirolimus 8%
38. Spine 8%
39. Bone and Bones 8%
40. Response Evaluation Criteria in Solid Tumors 7%
41. Somatomedin Receptors 7%
42. Chondrosarcoma 7%
43. Neoplasm Metastasis 7%
44. Glutamine 7%
45. Irinotecan 6%
46. Radiation 6%
47. Prodrugs 6%
48. Docetaxel 6%
49. Fluorouracil 6%
50. cemadotin 6%